KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

AbCellera Biologics (ABCL) Other Gross PP&E Adjustments (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Other Gross PP&E Adjustments for 6 consecutive years, with $223.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Gross PP&E Adjustments rose 7.05% year-over-year to $223.4 million, compared with a TTM value of $223.4 million through Sep 2025, up 7.05%, and an annual FY2024 reading of $210.3 million, up 36.41% over the prior year.
  • Other Gross PP&E Adjustments was $223.4 million for Q3 2025 at AbCellera Biologics, up from $219.6 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $304.7 million in Q1 2025 and bottomed at $31.0 million in Q1 2021.
  • Average Other Gross PP&E Adjustments over 5 years is $180.6 million, with a median of $208.7 million recorded in 2024.
  • The sharpest move saw Other Gross PP&E Adjustments surged 332.35% in 2021, then fell 19.22% in 2025.
  • Year by year, Other Gross PP&E Adjustments stood at $101.6 million in 2021, then surged by 52.39% to $154.9 million in 2022, then decreased by 0.47% to $154.2 million in 2023, then skyrocketed by 36.41% to $210.3 million in 2024, then grew by 6.22% to $223.4 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for ABCL at $223.4 million in Q3 2025, $219.6 million in Q2 2025, and $304.7 million in Q1 2025.